Nektar Therapeutics (NKTR) Revenue (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Revenue of $10.9 million for Q1 2026, up 3.83% year-over-year from $10.5 million in Q1 2025, and down 50.19% quarter-over-quarter from $21.8 million in Q4 2025.
Nektar Therapeutics (NKTR) Revenue (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Revenue history runs 17 years deep, the most recent figure standing at $10.9 million for Q1 2026.
- In Q1 2026, Revenue rose 3.83% year-over-year to $10.9 million; the TTM figure through Mar 2026 stood at $55.6 million (down 36.24% YoY), while the FY2025 annual figure was $55.2 million, down 43.89% from the prior year.
- Revenue for Q1 2026 stood at $10.9 million, down from $21.8 million in the prior quarter.
- The five-year high for Revenue was $29.2 million in Q4 2024, with the low at $10.5 million in Q1 2025.
- The 5-year median for Revenue is $21.8 million (2025), against an average of $20.4 million.
- The sharpest annual moves came in 2024 and 2025: Revenue climbed 22.15% in 2024, then sank 52.42% in 2025.
- Nektar Therapeutics' Revenue stood at $22.0 million in 2022, then grew by 8.45% to $23.9 million in 2023, then climbed by 22.15% to $29.2 million in 2024, then slipped by 25.25% to $21.8 million in 2025, then sank by 50.19% to $10.9 million in 2026.
- Business Quant data shows NKTR's Revenue at $10.9 million in Q1 2026, $21.8 million in Q4 2025, and $11.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | 10.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.86 Mn |
| Dec 31, 2025 | 21.81 Mn |
| Sep 30, 2025 | 11.79 Mn |
| Jun 30, 2025 | 11.18 Mn |
| Mar 31, 2025 | 10.46 Mn |
| Dec 31, 2024 | 29.18 Mn |
| Sep 30, 2024 | 24.12 Mn |
| Jun 30, 2024 | 23.49 Mn |
| Mar 31, 2024 | 21.64 Mn |
| Dec 31, 2023 | 23.89 Mn |
| Sep 30, 2023 | 24.14 Mn |
| Jun 30, 2023 | 20.50 Mn |
| Mar 31, 2023 | 21.59 Mn |
| Dec 31, 2022 | 22.02 Mn |
| Sep 30, 2022 | 23.63 Mn |
| Jun 30, 2022 | 21.59 Mn |
| Mar 31, 2022 | 24.82 Mn |
| Dec 31, 2021 | 25.01 Mn |
| Sep 30, 2021 | 24.92 Mn |
| Jun 30, 2021 | 28.33 Mn |